<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495040</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0977</org_study_id>
    <secondary_id>NCI-2012-01503</secondary_id>
    <secondary_id>P01CA021239-30</secondary_id>
    <nct_id>NCT00495040</nct_id>
  </id_info>
  <brief_title>Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if escalated/accelerated proton
      radiotherapy can improve the control of Non-Small Cell Lung Cancer (NSCLC) and decrease side
      effects. The safety of this treatment will also be studied.

      Objectives:

      To assess the therapeutic efficacy and toxicities of proton radiotherapy with
      escalated/accelerated dose for patients with medically inoperable stage I (T1-2, N0,M0)
      NSCLC.

      Primary goals:

        1. Improve 2 years progression free survival at the primary site, and

        2. reduce acute and chronic toxicity

      Secondary goals:

        1. Improve disease specific survival at 2 years.

        2. Study the potential of pre- and post treatment PET/CT in predicting clinical outcome.

        3. Study the role of biomarkers in predicting therapeutic response and toxicities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A proton beam is made up of charged particles that have a well-defined range of penetration
      into tissues. How deep it can penetrate is decided by both the beam's energy and the density
      of the tissue through which it passes. As the proton beam penetrates the body, the particles
      slow down, and the beam deposits its dose sharply near the end of its range. This is a
      phenomenon known as the Bragg peak. By adjusting the Bragg peak, the doctor can deliver a
      full, localized, uniform dose of energy to the treatment site while sparing the surrounding
      normal tissues. The proton beam is ideal for treatments where organ preservation is very
      important, such as lung cancer. Researchers know that standard photon radiotherapy is not
      able to adequately control tumor growth. But unfortunately, it is not possible to increase
      the dose of photon radiotherapy without also significantly increasing the side effects. In
      this study, using proton radiotherapy, researchers will increase the dose about 40% higher
      than standard photon radiotherapy.

      Screening Tests

      Signing this consent form does not mean that you will be able to take part in this study. You
      will have &quot;screening tests&quot; to help the doctor decide if you are eligible to take part in
      this study. The following tests and procedures will be performed before starting treatment on
      this study:

      Your complete medical history will be recorded. You will have a physical exam. Blood (about 4
      teaspoons) will be drawn (within 30 days) for the routine blood tests You will have a
      computed tomography (CT) scan or positron emission tomography (PET/CT) scan of the chest, an
      MRI scan or CT of the brain, You will have a lung function test. Women who are able to have
      children must have a negative blood-pregnancy test. You will have a 4DCT.

      Study Drug Administration If you are found to be eligible to take part in this study, you
      will receive 35 treatments of proton radiotherapy (radiotherapy does not have to start on a
      Monday but it cannot start on a Friday; usually Monday through Thursday for 7 to 8 weeks).
      During the treatment, you will lie still on a table for about 30-45 minutes per day in the
      same position. The proton machine will deliver the dose according to the plan designed by the
      physician and controlled by a computer. You will not feel, see, or smell anything during the
      proton beam delivery.

      During the treatment, you will be seen by a doctor and research nurse once a week to evaluate
      possible side effects. You will have a physical exam and you will have a medical history.

      You will be taken off study early if the disease gets worse or intolerable side effects
      occur. After finishing the treatment, follow up is recommended 6 weeks after completion of
      radiotherapy, required every 3 months (+/-1 month) for two years, then every (+/-1 month) 6
      months for three years, and then once a year for 2 years. You will have imaging tests (chest
      CT or PET scan), lung function test and routine blood tests (about 2 teaspoons) at the
      follow-up visits. You are allowed to have further chemotherapy or other treatment while you
      are still in the follow-up on this study. You should discuss chemotherapy with your medical
      oncologist.

      This is an investigational study. Proton radiotherapy is FDA approved for the treatment of
      lung cancer treatment. Up to 40 patients will take part in this study. All will be enrolled
      at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2006</start_date>
  <completion_date type="Actual">June 14, 2017</completion_date>
  <primary_completion_date type="Actual">June 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival and Progression Free Survival</measure>
    <time_frame>The Overall survival (OS): time of registration to the last follow-up (f/u), or lost to f/u, or death up to 5 years. The progression free survival (PFS): time of registration to any local-regional recurrence or distant metastasis up to 5 years.</time_frame>
    <description>Chest CT with contrast (if possible) was used for evaluation of Local control. If is suspicious for recurrence by CT image, PET or PET/CT scan is required and biopsy is recommended to confirm the recurrence. Continuing CT or PET images follow up for un-confirmed recurrent disease. Timing of recurrence: at the time of first image (PET and/or CT) showing abnormalities. PET will use for progression free survival (PFS).
Participants were followed up at 6 weeks after the completion of RT, every 3 months (±1 month) for 2 years, every 6 months (±1 month) for 3 years, and then annually. The Overall survival: time of registration to the last follow-up (f/u), or lost to f/u, or death. The PFS: time of registration to any local-regional recurrence or distant metastasis. Free local recurrence rate: time of registration to local recurrence. Free regional recurrence rate: time of registration to regional recurrence. Free distant metastasis rate: time of registration to distant metastasis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Proton Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiotherapy</intervention_name>
    <description>87.5 CGE with 2.5 Gy/fraction for 35 treatments</description>
    <arm_group_label>Proton Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically documented NSCLC.

          2. Patients with inoperable centrally located tumors, defined as those within 2 cm of the
             bronchial tree, major vessels, esophagus, heart, or other mediastinal structures but
             no direct invasion, T1N0M0 (stage IA), or any location of T2N0M0 (stage IB) and T3N0M0
             (selected stage II with chest wall involvement) NSCLC.

          3. Performance score KPS 60-100.

        Exclusion Criteria:

          1. Prior radiotherapy to the chest.

          2. Previous or concomitant malignancy other than (a) curatively treated carcinoma in situ
             of cervix, (b) basal cell carcinoma of the skin, (c) curatively treated superficial
             transitional cell carcinoma of the urinary bladder, and (d) early stage tumor treated
             more than 3 years ago for cure.

          3. Pregnancy. Patients, both men and women of child bearing potential should use an
             effective method of birth control throughout their participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Y. Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <results_first_submitted>February 26, 2018</results_first_submitted>
  <results_first_submitted_qc>December 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Proton Radiotherapy</keyword>
  <keyword>Proton Beam</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT00495040/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>(1)Inoperable NSCLC;(2)T1N0M0 (stage IA) that was centrally or superiorly located ≤ 2 cm in all directions of any critical mediastinal structure; T2N0M0 in any location (stage IB, tumor size&gt;3 cm, with no upper size limit), or selected T3N0M0 (stage II,chest wall, mediastinal pleura, or parietal pericardium involvement) in any location (3)ECOG≤2</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose-escalated Proton Therapy for Early-stage NSCLC</title>
          <description>35 patients were treated with 87.5 Gy at 2.5 Gy/fraction of proton therapy, with fraction given once a day, 5 days per week. The biological effective dose was 109.4 Gy using α/β of 10</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose-escalated Proton Therapy for Early-stage Non-small Cell l</title>
          <description>35 patients were treated with 87.5 Gy at 2.5 Gy/fraction of proton therapy, with fraction given once a day, 5 days per week. The biological effective dose was 109.4 Gy using α/β of 10</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="66" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (KPS) Score</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>The Karnofsky Performance Score (KPS) ranking runs from 100 to 0, where 100 is &quot;perfect&quot; Normal health and 0 is death. Practitioners occasionally assign performance scores in between standard intervals of 10. The KPS was to allow physicians to evaluate a patient's survival. The higher KPS scores, the better treatment outcome.</population>
          <units>units on a scale (%)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="60" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gross Tumor Volume (GTV)</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>In this study, Gross tumor volume is all known gross disease as demonstrated on end ventilation data set (30% phase as determined by Varian RPM or equivalent respiratory monitoring system) of the planning 4DCT using a lung window, and modified as deemed necessary based on PET/CT, diagnostic CT and other clinical studies.</population>
          <units>cubic centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" lower_limit="4.2" upper_limit="435.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>iCTV (internal Clinical Target Volume)</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>iCTV (internal Clinical Target Volume): Volume encompassing the Clinical Target Volume (CTV) and Internal Margin (IM). (iCTV = CTV + IM).
In this study, the iCTV is envelope of motion of the CTV estimated by an 8-mm isotropic expansion of the iGTV to encompase microextensions of the tumor (iCTV = iGTV+8mm);</population>
          <units>cubic centimeters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123" lower_limit="14.3" upper_limit="786.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Treatment Pulmonary Function - FEV1</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>percentage of predicted (%)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="18" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Treatment Pulmonary Function - DLCO</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>percentage of predicted (%)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="18" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Pulmonary Disease</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>COPD</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Emphysema</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pulmonary Fibrosis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Histological Type</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Squamous cell carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adenocarcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Squamous cell carcinoma + adenocarcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neuroendocrine carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-small cell carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Tumor Location</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Central or Superior</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Peripheral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Tumor size</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤3 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 cm ≤ 5 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Primary Tumor (T) Stage</title>
          <description>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.
American Joint Committee on Cancer (6th):
T1:Tumor ≤3 cm in greatest dimension, T2:tumor&gt;3 cm; involve: main bronchus, the visceral pleura or ≥ 2 cm to the Carina; atelectasis or pneumonia, T3:Invades: chest wall, diaphragm, mediastinal pleura, parietal pericardium, or tumor &lt; 2 cm to the Carina, entire lung atelectasis or pneumonia, The earlier T staging, the better treatment outcome</description>
          <population>There were 35 out of 38 patients treated under the protocol and evaluable for data analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1:Tumor ≤3 cm in greatest dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2:tumor&gt;3 cm; involve: main bronchus, the viscera</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Clinical Stage</title>
          <description>AJCC (American Joint Committee on Cancer) TNM staging (6th): Stage IA :T1 N0 M0 Stage IB :T2 N0 M0 Stage IIA :T1 N1 M0 Stage IIB :T3 N0 M0. T describes size of tumor and any spread of cancer into nearby tissue; N describes spread of cancer to nearby lymph nodes; M describes metastasis (spread of cancer to other parts of body). Higher the T, N or M number, the larger the size of the tumor and/or more it has grown into nearby tissues, spread to lymph nodes or metastasized to distant organs, respectively. The earlier TNM staging, the better treatment outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival and Progression Free Survival</title>
        <description>Chest CT with contrast (if possible) was used for evaluation of Local control. If is suspicious for recurrence by CT image, PET or PET/CT scan is required and biopsy is recommended to confirm the recurrence. Continuing CT or PET images follow up for un-confirmed recurrent disease. Timing of recurrence: at the time of first image (PET and/or CT) showing abnormalities. PET will use for progression free survival (PFS).
Participants were followed up at 6 weeks after the completion of RT, every 3 months (±1 month) for 2 years, every 6 months (±1 month) for 3 years, and then annually. The Overall survival: time of registration to the last follow-up (f/u), or lost to f/u, or death. The PFS: time of registration to any local-regional recurrence or distant metastasis. Free local recurrence rate: time of registration to local recurrence. Free regional recurrence rate: time of registration to regional recurrence. Free distant metastasis rate: time of registration to distant metastasis.</description>
        <time_frame>The Overall survival (OS): time of registration to the last follow-up (f/u), or lost to f/u, or death up to 5 years. The progression free survival (PFS): time of registration to any local-regional recurrence or distant metastasis up to 5 years.</time_frame>
        <population>Kaplan–Meier curves used for overall survival, progression-free survival, local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival. Differences between pairs of Kaplan–Meier curves were using the log-rank test. The Fisher’s exact test was used to compare local, regional, and distant recurrence rates.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose-escalated Proton Therapy for Early-stage Non-small Cell l</title>
            <description>35 patients were treated with 87.5 Gy at 2.5 Gy/fraction of proton therapy, with fraction given once a day, 5 days per week. The biological effective dose was 109.4 Gy using α/β of 10</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival and Progression Free Survival</title>
          <description>Chest CT with contrast (if possible) was used for evaluation of Local control. If is suspicious for recurrence by CT image, PET or PET/CT scan is required and biopsy is recommended to confirm the recurrence. Continuing CT or PET images follow up for un-confirmed recurrent disease. Timing of recurrence: at the time of first image (PET and/or CT) showing abnormalities. PET will use for progression free survival (PFS).
Participants were followed up at 6 weeks after the completion of RT, every 3 months (±1 month) for 2 years, every 6 months (±1 month) for 3 years, and then annually. The Overall survival: time of registration to the last follow-up (f/u), or lost to f/u, or death. The PFS: time of registration to any local-regional recurrence or distant metastasis. Free local recurrence rate: time of registration to local recurrence. Free regional recurrence rate: time of registration to regional recurrence. Free distant metastasis rate: time of registration to distant metastasis.</description>
          <population>Kaplan–Meier curves used for overall survival, progression-free survival, local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival. Differences between pairs of Kaplan–Meier curves were using the log-rank test. The Fisher’s exact test was used to compare local, regional, and distant recurrence rates.</population>
          <units>percentage of participants (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Survival rate : 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Survival rate : 2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Survival rate : 3 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Survival rate : 5 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression Free Survival rate : 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression Free Survival rate : 2 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression Free Survival rate : 3 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression Free Survival rate : 5 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>free local recurrence rate 5-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>free from regional recurrence rate: 5-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>free from distant metastasis rate: 5-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of registration to the time of the adverse event start date, up to 5 years.</time_frame>
      <desc>Grade &gt; 3 acute and chronic toxicities by Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE 3.0) will be analyzed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose-escalated Proton Therapy for Early-stage Non-small Cell l</title>
          <description>35 patients were treated with 87.5 Gy at 2.5 Gy/fraction of proton therapy, with fraction given once a day, 5 days per week. The biological effective dose was 109.4 Gy using α/β of 10</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is phase I/II one arm study. The focus is safety and tolerability (toxicity). Therefore, there are no results about factors and better or worse outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chang,Joe Y.,M.D. / Radiation Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-563-2337</phone>
      <email>jychang@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

